Alexander N Shoushtari
Alliance for Clinical Trials in Oncology · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander N Shoushtari as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05111574 · Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryNational Cancer Institute (NCI) · active not recruiting · Anal Melanoma, Bladder Melanoma, Cervical Melanoma · principal investigator
- Ph2NCT01979523 · Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaNational Cancer Institute (NCI) · active not recruiting · Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 · principal investigator
- Ph2NCT01587352 · Vorinostat in Treating Patients With Metastatic Melanoma of the EyeNational Cancer Institute (NCI) · active not recruiting · Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2015 to 2026Named on NCT05111574
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2014 to 2026Named on NCT01979523, NCT01587352
- U01CA069856RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01587352
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2015 to 2026Named on NCT01587352
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:00 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- 297 citationsRCR 17.4
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2023264 citationsRCR 22.2
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.Clin Cancer Res · 2020223 citationsRCR 8.8
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).J Clin Oncol · 2018218 citationsRCR 7.5
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.Nat Med · 2022150 citationsRCR 9.7
- Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.JAMA Oncol · 2018126 citationsRCR 3.9
- Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.Clin Cancer Res · 2017112 citationsRCR 3.2
- Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.Mol Cancer Ther · 202055 citationsRCR 2.6
- A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.Clin Cancer Res · 202039 citationsRCR 1.6